Global Human Respiratory Syncytial Virus (RSV) Treatment Market
A syncytial virus is a multi-nucleated virus which results from multiple cell fusions. Human respiratory syncytial virus (RSV) has a size of around 120 to 200 nm and is an enveloped virus with a linear minus-sense RNA genome. Human respiratory syncytial virus (RSV) causes complications such as bronchiolitis, asthma, chronic respiratory tract infections and acute otitis media in patients. Human respiratory syncytial virus (RSV) infects the lungs and breathing passages. Human respiratory syncytial virus (RSV) infection is experienced as a mild cold in healthy individuals while it can cause serious complications in infants and children younger than one year.
A syncytial virus is a multi-nucleated virus which results from multiple cell fusions. Human respiratory syncytial virus (RSV) has a size of around 120 to 200 nm and is an enveloped virus with a linear minus-sense RNA genome. Human respiratory syncytial virus (RSV) causes complications such as bronchiolitis, asthma, chronic respiratory tract infections and acute otitis media in patients. Human respiratory syncytial virus (RSV) infects the lungs and breathing passages. Human respiratory syncytial virus (RSV) infection is experienced as a mild cold in healthy individuals while it can cause serious complications in infants and children younger than one year.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong> <strong>Human</strong><br />
<strong>Respiratory</strong> <strong>Syncytial</strong><br />
<strong>Virus</strong> (<strong>RSV</strong>)<br />
<strong>Treatment</strong> <strong>Market</strong><br />
Share, <strong>Global</strong> Trends,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation and Forecast,<br />
2016 – 2026<br />
Future <strong>Market</strong> Insights<br />
www.futuremarketinsights.com<br />
sales@futuremarketinsights.com
Report Description<br />
A syncytial virus is a multi-nucleated virus which results from multiple cell fusions. <strong>Human</strong><br />
respiratory syncytial virus (<strong>RSV</strong>) has a size of around 120 to 200 nm and is an enveloped virus<br />
with a linear minus-sense RNA genome. <strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) causes<br />
complications such as bronchiolitis, asthma, chronic respiratory tract infections and acute otitis<br />
media in patients. <strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) infects the lungs and breathing<br />
passages. <strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) infection is experienced as a mild cold in<br />
healthy individuals while it can cause serious complications in infants and children younger than<br />
one year.<br />
<strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong>: Drivers & Restraints<br />
<strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) is a syncytial virus which causes respiratory tract<br />
infections, particularly the lower respiratory tract infections in infants and children. The<br />
prophylaxis for <strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) treatment is in the form of medications.<br />
Infants and children become weak after recovery and continue to spread the virus for the next<br />
one to three weeks. The <strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) infection can infect people of<br />
any ages but the severity is low in adults while infants and children with weakened immune<br />
systems show high severity of the infection. The growing number of patient cases is expected to<br />
drive the market growth while the lack of appropriate in-vitro facilities for conducting research<br />
studies for newer treatment alternatives is projected to hamper the market growth with a high<br />
impact over 2026.
Report Description<br />
<strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong>: Segmentation<br />
<strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong> is classified on the basis of<br />
treatment, end use and geography.<br />
Based on treatment, the global <strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong> is<br />
segmented into the following:<br />
• Supportive Care<br />
• Hospital Care<br />
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-<br />
1553<br />
Based on end use, the global <strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong> is<br />
segmented into the following:<br />
• Hospitals<br />
• 500 Beds<br />
• 200-400 Beds<br />
• Less than 200 Beds<br />
• Ambulatory Surgical Centres<br />
• Clinics
Report Description<br />
<strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong>: Overview<br />
As per the World Health Organization statistics, <strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) causes<br />
64 Mn infections and 160,000 deaths annually. Natural infection with <strong>Human</strong> respiratory<br />
syncytial virus (<strong>RSV</strong>) induces immunity against the virus which decreases over time. <strong>Human</strong><br />
respiratory syncytial virus (<strong>RSV</strong>) infections are recurrent. Currently, <strong>Human</strong> respiratory syncytial<br />
virus (<strong>RSV</strong>) infection lacks an approved vaccine therapy owing to limited number of studies in<br />
vitro and inability to culture the virus and maintain it in a stable state. As a result, the global<br />
<strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) market is anticipated to grow at a moderate CAGR<br />
during the forecast period from 2016 to 2026.<br />
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1553<br />
<strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong>: Region-wise Outlook<br />
Depending on geographic regions, global radiofrequency ablation system market is segmented<br />
into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia<br />
Pacific, Japan, and Middle East & Africa. According to the statistics of U.S. Department of Health<br />
& <strong>Human</strong> Services, it is estimated that more than half the total children population globally get<br />
infected with <strong>Human</strong> respiratory syncytial virus (<strong>RSV</strong>) within the first two years of birth. Owing<br />
to the viral infection outbreaks in winter and spring in North America, the diagnosis by a physical<br />
examination, chest x-rays to check for bronchiolitis, skin monitoring, blood tests for white cell<br />
counts and other laboratory tests for checking the respiratory secretions and treatment of
Report Description<br />
The viral infection through medications is expected to drive market growth in the region through<br />
the forecast period and contribute significantly to the global market.<br />
Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-gb-1553<br />
<strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>) <strong>Treatment</strong> <strong>Market</strong>: Key Players<br />
Some of the key market players identified in global <strong>Human</strong> <strong>Respiratory</strong> <strong>Syncytial</strong> <strong>Virus</strong> (<strong>RSV</strong>)<br />
<strong>Treatment</strong> <strong>Market</strong> are AstraZeneca, Arrow Therapeutics, Alnylam to name a few.
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting<br />
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and<br />
Retail.<br />
We have a global presence with delivery centers across India specializing in providing global research reports and country<br />
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for<br />
our client.<br />
Research<br />
Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Subscription Information<br />
Sector Coverage<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - <strong>Global</strong> Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com<br />
• Automotive and Transportation<br />
• Chemicals & Materials<br />
• Electronics, Semiconductor, and ICT • Food and Beverages<br />
• Retail and Consumer Products<br />
• Services and Utilities<br />
• Industrial Automation and Equipment • Energy, Mining, Oil, and<br />
• Healthcare, Pharmaceuticals & Medical Devices Gas
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
For other queries contact:<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705
Change language